Gnosis Introduces EdenDx for Early Endometrial Cancer Detection
Gnosis, a diagnostic lab advancing women's health through molecular innovation, has announced the launch of EdenDx, which stands for Early Detection for Endometrial Neoplasia. This test is a pioneering, non-invasive liquid-based cytology test designed specifically for the early detection of endometrial cancer in the U.S. market.
The Significance of Early Endometrial Cancer Detection
Endometrial cancer ranks as the fourth most prevalent cancer affecting women today, with projections indicating over 69,000 new cases annually. Unfortunately, many women receive their diagnoses at late stages. This often results from inconclusive imaging, discomfort surrounding traditional biopsy procedures, or limited access to specialized healthcare facilities.
Statistics suggest that nearly 30% of biopsies yield insufficient tissue samples, necessitating repeat procedures and prolonging the time before women receive definitive diagnoses. This unfortunate situation often leads to delays in treatment, underscoring a significant gap in women's healthcare.
A Closer Look at EdenDx
EdenDx harnesses the power of INEX's epiHERA™ technology to facilitate a straightforward method for early endometrial cancer diagnosis. Its ease of use begins at a routine pelvic exam, where a clinician collects an endocervical sample using a cervical brush, which is then preserved in a ThinPrep® vial.
The test works by detecting hypermethylation of two genes, CDO1 and CELF4, known to be closely linked to endometrial cancer. Additionally, results become available quickly—typically between three to seven days—allowing healthcare providers to assess risks and make timely clinical decisions.
Dr. Safedin Beqaj, Clinical Laboratory Director at Gnosis, emphasized, "EdenDx was designed to close a critical gap in women's health and provide an accessible molecular test fitting seamlessly into routine care. Our mission is to help women receive timely answers without disrupting their normal healthcare procedures."
Addressing the Needs of High-Risk Populations
Gnosis developed EdenDx to specifically target women frequently overlooked by standard diagnostic protocols. The test presents a non-invasive option for women who experience abnormal uterine bleeding, chronic anovulation, postmenopausal symptoms, or high Body Mass Index (BMI). Additionally, it accommodates those with a history of endometrial hyperplasia, exposure to Tamoxifen therapy, or those with a family history of Lynch syndrome.
Currently, tens of millions of women fall into these high-risk categories. In the U.S., over 34 million women live with an elevated BMI, and about 6 million are affected by polycystic ovary syndrome (PCOS). Many women with hereditary cancer risks remain untreated or undiagnosed until their symptoms reach advanced stages.
Validation and Availability of EdenDx
In validation studies, EdenDx achieved remarkable results, demonstrating 97.8% specificity and 85.3% sensitivity, even in cases of high-grade tumors. While significantly reducing unnecessary biopsies and enhancing care efficiency, it's vital to note that EdenDx is not intended to replace traditional biopsies, which are still necessary for a definitive diagnosis.
Healthcare providers can readily begin offering EdenDx alongside routine well-woman and pelvic examinations, allowing women to benefit from this innovative testing approach promptly.
Commitment to Women’s Health
Gnosis is dedicated to developing diagnostics that resonate with the real-world needs of healthcare providers and patients alike. EdenDx embodies this commitment by broadening access to early detection through practical and scalable technology tailored for women requiring timely care.
About Gnosis
Gnosis is a CLIA- and CAP-accredited diagnostic laboratory specializing in advanced testing, molecular diagnostics, and pharmacogenomics for women’s health. Formerly known as Mountain View Medical Laboratory, Gnosis is committed to community-focused innovation that empowers healthcare providers to make confident, informed decisions.
Frequently Asked Questions
What is EdenDx?
EdenDx is a non-invasive liquid-based cytology test specifically designed for the early detection of endometrial cancer.
How does the EdenDx testing process work?
An endocervical sample is collected during a routine pelvic exam and analyzed for hypermethylation of specific genes associated with endometrial cancer.
What is the turnaround time for EdenDx results?
Results from the EdenDx test are typically available within three to seven days, enabling timely decision-making for healthcare providers.
Who can benefit from the EdenDx test?
The test is particularly beneficial for women with abnormal uterine bleeding, high BMI, or a history of endometrial issues, as well as those at higher risk due to genetic factors.
Where can healthcare providers offer the EdenDx test?
Healthcare providers can offer EdenDx alongside routine well-woman and pelvic exams, providing a seamless addition to standard women's health assessments.
